Trials and tribulations of trial design in critical care: the example of CMV prophylaxis in the critically ill

Please join us …

When: Tuesday, October 30, 2018, 12–1 p.m.

Where: ICES, G-Wing, Conference Centre (Sunnybrook Health Sciences Centre)

Who: Gordon Rubenfeld, MD, MSc, FRCPC; Professor, Medicine, Interdepartmental Division of Critical Care Medicine, University of Toronto.

Topic: Trials and tribulations of trial design in critical care: the example of CMV prophylaxis in the critically ill

Learning objectives

1. Understanding the pathobiology of CMV reactivation in the “immunocompetent” ICU patient
2. Reviewing the preliminary data on the role of ganciclovir prophylaxis in this population
3. Reviewing the challenges of designing a feasible phase III trial for this therapy covering issues of non-mortal ICU outcomes that are clincially persuasive, the effect of treatment effect heterogeneity on sample size and identification, and the tradeoffs in feasibility, cost, and enrolment
   .

Gordon Rubenfeld